Burden and outcomes for complex perianal fistulas in Crohn’s disease: Systematic review

Julián Panés(Hospital Clínic de Barcelona), Haridarshan Patel(Amgen (United States))

World Journal of Gastroenterology

November 13, 2018

10.3748/wjg.v24.i42.4821

Cited by 98

Related Papers

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

|The American Journal of Gastroenterology|2015|1.8k

Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

|Journal of Crohn s and Colitis|2013|669

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

|The Lancet|2017|449

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

|The Lancet|2022|383

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

|The Lancet|2023|350